yellow fever vaccine: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
yellow fever vaccine: clinical details
Prescribing considerations
- Confirm genuine exposure risk or a certificate requirement from the current itinerary.
- Assess immunosuppression, thymus disease or thymectomy, severe allergy, pregnancy, breastfeeding and previous vaccine reactions.
- For people aged 60 years or older, vaccinate only when exposure risk is significant and unavoidable because serious neurological and viscerotropic reactions are more frequent.
- Children aged 6 to under 9 months require specialist risk assessment and vaccination only in exceptional circumstances under official guidance.
- Use the subcutaneous route with bleeding disorders, thrombocytopenia or anticoagulant treatment; never administer intravascularly.
Contraindications and cautions
- Hypersensitivity to the vaccine, its excipients, eggs or chicken proteins, or a severe reaction to a previous yellow fever vaccine.
- Age under 6 months.
- Congenital or acquired immunosuppression, including clinically significant treatment-related immunosuppression.
- Thymus dysfunction, including thymoma or myasthenia gravis, or previous thymectomy for any reason.
- Symptomatic HIV infection, or asymptomatic HIV infection with impaired immune function.
- Moderate or severe febrile illness or acute illness.
Monitoring
- Record the product name and batch number for traceability.
- Ensure facilities and trained staff are available to manage anaphylaxis and vaccination-related fainting.
- Advise recipients to report severe systemic or neurological symptoms and mention their recent vaccination.
- Consider specialist assessment or relevant laboratory evidence where HIV status or recovery from temporary immunosuppression affects eligibility.
Clinical pharmacology
A live attenuated 17D-204 strain vaccine produced in specified pathogen-free chick embryos. Limited replication induces neutralising antibodies and virus-specific cellular immunity; conventional pharmacokinetic studies do not apply.
Formulation and product differences
- Supplied as a powder with sodium chloride solvent in a pre-filled syringe and reconstituted before administration.
- After reconstitution, it forms a beige to pink-beige, variably opalescent suspension that must be used immediately.
- Some pre-filled syringe tip caps contain a natural-rubber latex derivative.
- Contains sorbitol and is essentially sodium-free and potassium-free.
yellow fever vaccine interactions
Give the vaccination centre a complete medicines and vaccination history.
Immunosuppressive medicines, including high-dose systemic corticosteroids, biological therapies and cytotoxic chemotherapy
Vaccination is contraindicated while clinically immunosuppressed because the live vaccine virus may replicate excessively. Obtain specialist advice if immune status is uncertain.
Radiotherapy
Vaccination is contraindicated when treatment causes immunosuppression and should be deferred until immune recovery is assessed.
Other injectable vaccines
They must not be mixed in the same syringe and should be injected at separate sites when given at the same visit.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.